MedTrace Logo

Allopurinol for Renal Transplant Associated Hypertension in Children

NCT00288171 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2017-09-13

No results posted yet for this study

Summary

To test the hypothesis that lowering serum uric acid will ameliorate hypertension in children after renal transplantation.

Conditions

Interventions

DRUG

Placebo

placebo capsule twice daily for one month

DRUG

Allopurinol

Allopurinol 200mg twice daily for one month

Sponsors & Collaborators

  • Baylor University

    collaborator OTHER

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    lead NIH

Principal Investigators

  • Daniel I Feig, MD, PhD · Baylor College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
6 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2008-01-31
Completion
2008-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00288171 on ClinicalTrials.gov